Try our Advanced Search for more refined results
In re Chembio Diagnostics, Inc. Securities Litigation
Case Number:
2:20-cv-02706
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Block & Leviton
- Glancy Prongay
- Honigman LLP
- Kaplan Fox
- K&L Gates
- Latham & Watkins
- Levi & Korsinsky
- Pomerantz LLP
- Robbins Geller
- Rolnick Kramer
Companies
- Chembio Diagnostics Inc.
- Dougherty & Company LLC
- Municipal Employees' Retirement System of Michigan
- Robert W. Baird & Co. Inc.
Sectors & Industries:
-
April 25, 2023
COVID-19 Test Maker Investors Seek Final OK For $8.1M Deal
Investors in Chembio Diagnostics Inc., a company that sold now-revoked COVID-19 tests, have asked a New York federal court to give a final OK to an $8.1 million deal to end a lawsuit alleging that shareholders were harmed when the company's tests were taken off the market after being deemed ineffective by the U.S. Food and Drug Administration.
-
August 18, 2020
8 Firms Bid To Lead Stock Suit Over Revoked COVID-19 Test
Lowenstein Sandler LLP and Robbins Geller Rudman & Dowd LLP appear to be leading the fight to helm a putative securities class action against a diagnostics company that had its COVID-19 antibody test revoked by the U.S. Food and Drug Administration.
-
June 19, 2020
Diagnostics Co. Sued After COVID-19 Test Revoked By FDA
Chembio Diagnostics Inc., a point-of-care diagnostics company that saw its stock price explode in the early stages of the coronavirus pandemic, was sued Thursday after authorization for its COVID-19 antibody test was revoked by the U.S. Food and Drug Administration.